People who stayed on a 7.2 milligram weekly dose of semaglutide lost around 20% of their body weight over 72 weeks.

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. With approximately 70% of American adults meeting the criteria for being obese or ...

Sales of blockbuster weight-loss drugs have surged in 2024 and are projected to continue rising in the coming years. The ...

The only way to get Ozempic online is with a prescription from a licensed healthcare professional. The FDA has approved it for treating type 2 diabetes, and it is often used off-label to aid ...

Neither drug is considered as effective as the brand-name weekly injections sold for diabetes and weight loss as Ozempic and Wegovy by Novo Nordisk and Mounjaro and Zepbound by Eli Lilly.

Tesla chief Elon Musk dubbed himself “Ozempic Santa” in an X post on Christmas Day, marking the tech billionaire’s latest show of support for weight-loss drugs as he has pushed for making ...

DEAR DR. ROACH: After about 10 months of being on Ozempic and working my way up to a 1-mg dose, I lost 40 pounds effortlessly. Sugar cravings disappeared as if by magic. I then noticed myself ...

Does berberine offer a natural alternative to medications like Ozempic, as many users on social media claim? “Berberine has shown to help with weight loss, but in comparison to Ozempic ...

They called 2023 the year of Ozempic, but it now seems GLP-1 drugs might define an entire decade — or an even longer era. The game-changing drugs, which mimic the hormone GLP-1, offer large ...

The active ingredient in Ozempic and Wegovy, a drug called semaglutide, can have direct beneficial effects on the heart within weeks, in addition to the longer-term benefits of losing weight ...

Ozempic manufacturer Novo Nordisk said patient safety is a priority and “the benefit-risk profile of semaglutide remains unchanged” Ricardo Rubio/Europa Press via Getty Health officials in ...

Danish health authorities are asking the European Union to review two studies linking Novo Nordisk's diabetes drug, Ozempic, to a rare eye condition. The rare eye condition, referred to as non ...